Nexstim (NXTMH) H2 2024 earnings summary

Executive summary

• Revenue grew 20.5% year-over-year to EUR 8.7M in 2024, with both diagnostic and therapy segments contributing.

• Achieved positive EBITDA for the first time at EUR 0.3M, turning from a loss of EUR 0.5M in 2023.

• Strategic partnerships formed with Brainlab AG for development and distribution, and Sinaptica Therapeutics for Alzheimer’s therapy co-development.

• Cash flow from operations improved to EUR 1.9M from -EUR 2.3M year-over-year.

Financial highlights

• H2 2024 revenue was EUR 5.6M, up 17.2% from H2 2023; full-year revenue reached EUR 8.7M, up 20.5%.

• Gross margin for 2024 was 79.0%, up from 77.9% in 2023.

• Operating result improved to -EUR 0.5M from -EUR 1.2M year-over-year.

• Net result for 2024 was -EUR 0.9M, compared to -EUR 1.3M in 2023.

• Cash and cash equivalents at year-end were EUR 3.9M, up from EUR 1.5M.

Outlook and guidance

• Revenue and operating profit are expected to improve in 2025, supported by strengthened global distribution and new product launches.

• Strategic focus on profitable growth, minimizing future capital needs, and expanding US clinical partnerships.

• Focus remains on expanding the partnership network and launching the NBS 6 diagnostic device.